Literature DB >> 18571543

Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.

Ozlem Goker-Alpan1, Edythe A Wiggs, Michael J Eblan, William Benko, Shira G Ziegler, Ellen Sidransky, Raphael Schiffmann.   

Abstract

OBJECTIVE: To investigate the spectrum and prevalence of cognitive deficits among children with type 3 (chronic neuronopathic) Gaucher disease (GD). STUDY
DESIGN: A case review study identified 32 children (male/female; 17:15) with type 3 GD who had received enzyme replacement therapy (ERT) or a bone marrow transplant. The diagnosis of GD was established by enzymatic assay and DNA testing. Subjects were assessed with standard neuropsychological testing, and data from the most recent evaluation were included.
RESULTS: Neuropsychometric assessments demonstrated a wide spectrum of full-scale IQ scores ranging from 39 to 124 (mean 75). About 60% of subjects had intellectual skills below average. There were significant discrepancies between verbal and performance IQ, with a range between -6 and 38 points (P = .02). This gap was more prominent in older subjects, with better performance in the verbal areas. No correlation was observed between intelligence measures and genotype or the extent of systemic involvement. The dosage, age at initiation, and the length of ERT had no significant effect on IQ scores.
CONCLUSIONS: In type 3 GD, cognitive deficits, characterized by visual-spatial dysfunction, are common but underappreciated and appear resistant to ERT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571543     DOI: 10.1016/j.jpeds.2007.12.023

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  21 in total

1.  Enzyme replacement in neuronal storage disorders in the pediatric population.

Authors:  Erika F Augustine; Jonathan W Mink
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 2.  Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).

Authors:  Markus Ries
Journal:  J Inherit Metab Dis       Date:  2017-03-17       Impact factor: 4.982

3.  Non-iminosugar glucocerebrosidase small molecule chaperones.

Authors:  Juan Jose Marugan; Wenwei Huang; Omid Motabar; Wei Zheng; Jingbo Xiao; Samarjit Patnaik; Noel Southall; Wendy Westbroek; Wendy A Lea; Anton Simeonov; Ehud Goldin; Maria A Debernardi; Ellen Sidransky
Journal:  Medchemcomm       Date:  2011-10-24       Impact factor: 3.597

4.  EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review.

Authors:  Chelsie N Poffenberger; Sara Inati; Nahid Tayebi; Barbara K Stubblefield; Emory Ryan; Raphael Schiffmann; Ellen Sidransky; Grisel Lopez
Journal:  Mol Genet Metab       Date:  2020-10-20       Impact factor: 4.797

Review 5.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

6.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

7.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

Review 8.  Gaucher disease: insights from a rare Mendelian disorder.

Authors:  Ellen Sidransky
Journal:  Discov Med       Date:  2012-10       Impact factor: 2.970

9.  Pharmacotherapy of Gaucher Disease: Current and Future Options.

Authors:  Lunawati L Bennett; Chris Fellner
Journal:  P T       Date:  2018-05

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.